Cao Wenqing, Goolsby Charles L, Nelson Beverly P, Singhal Seema, Mehta Jayesh, Peterson Loann C
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Am J Clin Pathol. 2008 Jun;129(6):926-33. doi: 10.1309/8UVF7YQ1D4D4ETQV.
Little information has been reported describing antigen stability in plasma cell myeloma. In this study, the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen, were evaluated by flow cytometric analyses in 56 patients with plasma cell myeloma. Of the 56 patients, 23 (41%) showed immunophenotype change, including CD56 in 6 cases, CD20 in 7 cases, and CD52 in 17 cases. Combined CD56/CD52 change was seen in 3 cases and combined CD20/CD52 in 4 cases. No correlation was found between immunophenotype change and age, sex, stage, plasma cell morphologic features, extent of marrow involvement, time between analyses, type of therapy, or response to therapy. Immunophenotype shift was more common in patients with IgA than in patients with IgG paraprotein. Recognition of lack of stability in immunophenotype may be important, especially in antigen-directed treatment decisions and when specific phenotypes are used to detect residual disease.
关于浆细胞骨髓瘤中抗原稳定性的报道较少。在本研究中，通过流式细胞术分析评估了56例浆细胞骨髓瘤患者中2个潜在治疗靶点CD20和CD52以及经常异常表达的CD56抗原的表达频率和稳定性。56例患者中，23例（41%）出现免疫表型改变，其中6例为CD56改变，7例为CD20改变，17例为CD52改变。3例出现CD56/CD52联合改变，4例出现CD20/CD52联合改变。免疫表型改变与年龄、性别、分期、浆细胞形态学特征、骨髓受累程度、分析间隔时间、治疗类型或治疗反应之间均未发现相关性。免疫表型转变在IgA患者中比在IgG副蛋白患者中更常见。认识到免疫表型缺乏稳定性可能很重要，尤其是在抗原导向的治疗决策以及使用特定表型检测残留疾病时。
